Mibefradil dihydrochloride was previously used in the treatment of hypertension and chronic stable angina but was withdrawn from the market in 1998 due to serious drug interactions. It acts as a calcium channel blocker, primarily targeting T-type calcium channels (with some effect on L-type), which relaxes and widens blood vessels, improving blood flow and reducing blood pressure. This mechanism was effective for managing hypertension and angina-related chest pain. Currently, it is available as a research reagent. Its unique action on T-type channels has led to ongoing research for potential applications in other cardiovascular conditions, neurological disorders, and certain cancers, where it may inhibit cancer cell proliferation. Use in research requires careful consideration of potential interactions and toxicity, including liver effects.